Skip to content
National Association of Attorneys General
  • Issues
    • Issues
      • Anticorruption
      • Antitrust
      • Bankruptcy
      • Charities
      • Civil Law
    • Issues
      • Consumer Protection
      • Criminal Law
      • Cyber and Technology
      • Disaster Preparedness & Response
      • Elder Justice
    • Issues
      • Ethics
      • Human Trafficking
      • Medicaid Fraud
      • Opioids
      • Powers & Duties
    • Issues
      • Public Health
      • The U.S. Supreme Court
      • Tobacco
      • Veterans & Military
  • Our Work
    • Training & Research
    • Centers
      • Center for Supreme Court Advocacy
      • Center for Tobacco & Public Health
      • Center for Consumer Protection
    • Committees
    • Initiatives
      • Presidential Initiative
      • Strategic Partnerships
      • ConsumerResources.org
      • International Fellows
      • COVID-19
    • Bankruptcy
    • Policy & Advocacy
  • Events & Training
    • Event Calendar
    • Attorney General Symposium
    • Presidential Summit
    • Capital Forum
    • Region Meetings
    • CLE Credit
    • NAAG Trainings
    • Online Learning
    • NAMFCU Trainings
    • NAAG Faculty
  • News & Resources
    • Attorney General Journal
    • Reports & Publications
    • Newsroom
    • NAAG Policy Letters
    • Podcasts
    • Online Learning
    • Research & Data
    • Member Directory
  • Attorneys General
    • What Attorneys General Do
    • Who is my Attorney General?
    • Attorneys General Office 101
    • Research & Data
    • Awards & Recognition
    • Careers in Attorney General Offices
    • Careers in Medicaid Fraud Control Units
  • About NAAG
    • NAAG Staff
    • NAAG Leadership
    • NAAG Member Services
    • NAAG Regions
    • NAAG FAQs
    • SAGE
    • NAMFCU
    • Newsroom
    • Careers at NAAG
  • Find my AG
  • About NAMFCU
    • About the Medicaid Fraud Control Units
    • Reporting Fraud and Abuse
    • MFCU Member Hub
    • Careers with a MFCU
  • Contact Us
National Association of Attorneys General
  • Find My AG
  • Consumer Complaints
  • Member Benefits
  • Contact Us
Log In
  • Issues
    • Issues
      • Anticorruption
      • Antitrust
      • Bankruptcy
      • Charities
      • Civil Law
    • Issues
      • Consumer Protection
      • Criminal Law
      • Cyber and Technology
      • Disaster Preparedness & Response
      • Elder Justice
    • Issues
      • Ethics
      • Human Trafficking
      • Medicaid Fraud
      • Opioids
      • Powers & Duties
    • Issues
      • Public Health
      • The U.S. Supreme Court
      • Tobacco
      • Veterans & Military
  • Our Work
    • Training & Research
    • Centers
      • Center for Supreme Court Advocacy
      • Center for Tobacco & Public Health
      • Center for Consumer Protection
    • Committees
    • Initiatives
      • Presidential Initiative
      • Strategic Partnerships
      • ConsumerResources.org
      • International Fellows
      • COVID-19
    • Bankruptcy
    • Policy & Advocacy
  • Events & Training
    • Event Calendar
    • Attorney General Symposium
    • Presidential Summit
    • Capital Forum
    • Region Meetings
    • CLE Credit
    • NAAG Trainings
    • Online Learning
    • NAMFCU Trainings
    • NAAG Faculty
  • News & Resources
    • Attorney General Journal
    • Reports & Publications
    • Newsroom
    • NAAG Policy Letters
    • Podcasts
    • Online Learning
    • Research & Data
    • Member Directory
  • Attorneys General
    • What Attorneys General Do
    • Who is my Attorney General?
    • Attorneys General Office 101
    • Research & Data
    • Awards & Recognition
    • Careers in Attorney General Offices
    • Careers in Medicaid Fraud Control Units
  • About NAAG
    • NAAG Staff
    • NAAG Leadership
    • NAAG Member Services
    • NAAG Regions
    • NAAG FAQs
    • SAGE
    • NAMFCU
    • Newsroom
    • Careers at NAAG
  • Find my AG
  • About NAMFCU
    • About the Medicaid Fraud Control Units
    • Reporting Fraud and Abuse
    • MFCU Member Hub
    • Careers with a MFCU
  • Contact Us

Recent Congressional Action on Substance Use and What to Expect this Year

Home / Opioids / Recent Congressional Action on Substance Use and What to Expect this Year
May 19, 2021 Opioids, Substance Use
Share this

  • Ryan Greenstein
    Legislative Director and Special Assistant to the Executive Director
    National Association of Attorneys General

On Capitol Hill, there has been a flurry of activity on legislation related to expanding access to medication for opioid use disorder treatment, extending the classification of illicit fentanyl analogues as Schedule I under the Controlled Substances Act (CSA), and removing barriers to financial services for cannabis-related businesses. As the 117th Congress continues, below is a brief update on the status of key substance-related legislation and prospects for the remainder of the year.

Eliminating the DEA X-Waiver

On April 14, the House Energy and Commerce Committee’s Health Subcommittee held a hearing on challenges for combatting substance use disorder during the pandemic. Just two weeks prior to the hearing, the White House Office of National Drug Control Policy (ONDCP) Acting Director Regina LaBelle announced drug overdose deaths increased by approximately 27% during the COVID-19 pandemic over the previous year. As data continues to be released on the impact of the pandemic on the opioid crisis, there is increased optimism about quick action by Congress to combat factors contributing to the crisis.

One of the top priorities of the hearing was to examine how Congress can expand access to medication for opioid use disorder (OUD), including buprenorphine. Buprenorphine is one of three medications approved by the Food and Drug Administration (FDA) to treat OUD. In 2000, Congress imposed a requirement that any practitioners prescribing buprenorphine to treat OUD must first acquire a waiver from the Drug Enforcement Agency (DEA) known as a “DEA X-waiver.” Before acquiring this waiver, practitioners are required to receive at least eight hours of specialized training and agree to the DEA’s right to audit their medical office at any point. As a result of these restrictions, only 6% of all eligible practitioners have a DEA X-waiver and 40% of all counties in the country do not have a single waivered practitioner.

The Mainstreaming Addiction Treatment (MAT) Act, introduced by Rep. Paul Tonko (D-NY) and Rep. Michael Turner (R-OH), was referenced throughout the April 14 hearing as a solution to increasing the availability of buprenorphine. The bill, which has been endorsed by NAAG, would eliminate the DEA X-waiver requirement.

Acting ONDCP Director LaBelle spoke at length during the hearing about the administration’s recently announced drug policy priorities, which include expanding access to treatment and removing “unnecessary barriers to prescribing buprenorphine.” However, despite these statements supporting buprenorphine becoming more widely available for OUD treatment, Acting Director LaBelle declined to explicitly endorse the MAT Act when asked by Rep. Tonko. On April 27, two weeks after the hearing, the Biden administration released new federal guidelines removing certain requirements for practitioners seeking to prescribe buprenorphine to treat OUD. Unfortunately, these new guidelines by themselves cannot eliminate the DEA X-waiver which requires congressional action.

A similar push to eliminate the DEA X-waiver is ongoing in the Senate. In late March, a bipartisan coalition introduced CARA 3.0, which includes several proposed grant programs and reforms including elimination of the DEA X-waiver. One of the lead sponsors of CARA 3.0 is Sen. Maggie Hassan (D-NH), who is also leading the Senate version of the MAT Act with Sen. Lisa Murkowski (R-AK).

Scheduling of Illicit Fentanyl Analogues

Another topic addressed during the recent House Energy and Commerce Committee’s Health Subcommittee hearing was the fast-approaching expiration of a temporary DEA order that classified illicit fentanyl analogues as Schedule I drugs. Schedule I drugs are defined by the DEA as “drugs with no currently accepted medical use and a high potential for abuse.” Fentanyl, a synthetic opioid similar to morphine but much more potent, and many related fentanyl analogues have been largely responsible for the shocking uptick in synthetic opioid deaths in the past year.

The DEA’s initial temporary order expired on February 6, 2020 but was extended by Congress’ passage of the Temporary Reauthorization and Study of the Emergency Scheduling of Fentanyl Analogues Act. This legislation extended the classification until May 6, 2021 and passed in the Senate with unanimous consent. Sen. Rob Portman (R-OH) and Sen. Joe Manchin (D-WV) have also reintroduced the Federal Initiative to Guarantee Health by Targeting (FIGHT) Fentanyl Act, which has been endorsed by NAAG and would permanently classify illicit fentanyl analogues as Schedule I.

During the committee hearing, Acting ONDCP Director LaBelle pushed back on any permanent actions. She encouraged Congress to temporarily extend the classification to provide more time for agencies to conduct research on possible consequences of a permanent classification.

In the weeks following the hearing, numerous proposals to extend the temporary order gained momentum, though Congress has made it increasingly clear that a permanent classification through legislation has lost momentum. Days before the May 6 deadline, President Biden signed H.R. 2630, which extends the temporary order through September 30. Senate Judiciary Committee Ranking Member Chuck Grassley (R-IA) had also recently teamed up with Senators John Cornyn (R-TX) and Maggie Hassan (D-NH) to introduce the Temporary Extension of Fentanyl Scheduling Act of 2021, which would have gone further than H.R. 2630 by extending the temporary order through July 6, 2022. Like last year, the temporary extension guarantees that the debate over how to schedule illicit fentanyl analogues will continue this fall as September 30 approaches.

SAFE Banking Act

For the second time in as many Congresses, the Secure and Fair Enforcement Banking Act of 2021, also known as the SAFE Banking Act, passed the House of Representatives by a 321-101 margin on April 19. In 2019, the bill passed the House but never received a vote in the Senate. Its prospects during this Congress remain unclear.

The SAFE Banking Act would prevent federal regulators from penalizing financial institutions that provide services to legitimate cannabis-related businesses. Though most states have already legalized the use of cannabis for medical or recreational purposes, it is considered a Schedule I drug under the CSA, which prevents the banking industry from accepting any deposits from cannabis businesses. As legal cannabis sales are anticipated to double to over forty-one billion dollars between now and 2025, this legislation is intended to make it easier for cannabis-related companies to take advantage of the banking system and move away from relying on cash transactions. The lead sponsors also hope the legislation will make it easier for other industries, such as law firms or real estate companies, to engage with the cannabis industry.

During a White House press conference on April 20, White House Press Secretary Jen Psaki did not commit the President to supporting or opposing the SAFE Banking Act. However, she was firm in describing the President’s view that decisions regarding the legalization of recreational marijuana should be left to individual states and that the President supports rescheduling cannabis as a Schedule II drug. On this issue, the President differs from Senator Majority Leader Chuck Schumer (D-NY), who has recently come out in support of national legalization. Senate Banking, Housing and Urban Affairs Chair Sherrod Brown (D-OH) is adamant that  any cannabis legislation must include drug sentencing reform and several Republican senators still oppose the SAFE Banking Act, including Senate Banking, Housing and Urban Affairs Ranking Member Sen. Mike Crapo (R-ID), who formerly chaired the committee. Under these circumstances, the legislation faces numerous hurdles on its way to becoming law. Whether those hurdles will be overcome in the 117th Congress remains unclear.

The SAFE Banking Act was previously endorsed by NAAG during the 116th Congress. However, NAAG has not renewed that support in the 117th Congress. On April 1, 2021, the four lead attorneys general of the 2019 endorsement letter reiterated their own continued support to Congress in a letter to congressional leadership.

 

Related Posts

Related Posts

2025 Presidential Initiative Summit

Connect with NAAG and the Attorney General Community

Create a NAAG account to subscribe to our newsletters or mailing lists.

Create Account
Subscribe
Marble columns and the top of a federal building

scroll to filters

White Logo for the National Association of Attorneys General

1850 M Street NW
12th floor
Washington, DC 20036

TEL 202-326-6000
EMAIL 

Youtube
  • Issues
    • Issues
      • Anticorruption
      • Antitrust
      • Bankruptcy
      • Charities
      • Civil Law
    • Issues
      • Consumer Protection
      • Criminal Law
      • Cyber and Technology
      • Disaster Preparedness & Response
      • Elder Justice
    • Issues
      • Ethics
      • Human Trafficking
      • Medicaid Fraud
      • Opioids
      • Powers & Duties
    • Issues
      • Public Health
      • The U.S. Supreme Court
      • Tobacco
      • Veterans & Military
  • Our Work
    • Training & Research
    • Centers
      • Center for Supreme Court Advocacy
      • Center for Tobacco & Public Health
      • Center for Consumer Protection
    • Committees
    • Initiatives
      • Presidential Initiative
      • Strategic Partnerships
      • ConsumerResources.org
      • International Fellows
      • COVID-19
    • Bankruptcy
    • Policy & Advocacy
  • Events & Training
    • Event Calendar
    • Attorney General Symposium
    • Presidential Summit
    • Capital Forum
    • Region Meetings
    • CLE Credit
    • NAAG Trainings
    • Online Learning
    • NAMFCU Trainings
    • NAAG Faculty
  • News & Resources
    • Attorney General Journal
    • Reports & Publications
    • Newsroom
    • NAAG Policy Letters
    • Podcasts
    • Online Learning
    • Research & Data
    • Member Directory
  • Attorneys General
    • What Attorneys General Do
    • Who is my Attorney General?
    • Attorneys General Office 101
    • Research & Data
    • Awards & Recognition
    • Careers in Attorney General Offices
    • Careers in Medicaid Fraud Control Units
  • About NAAG
    • NAAG Staff
    • NAAG Leadership
    • NAAG Member Services
    • NAAG Regions
    • NAAG FAQs
    • SAGE
    • NAMFCU
    • Newsroom
    • Careers at NAAG
  • Find my AG
  • About NAMFCU
    • About the Medicaid Fraud Control Units
    • Reporting Fraud and Abuse
    • MFCU Member Hub
    • Careers with a MFCU
  • Contact Us
  • Find My AG
  • Consumer Complaints
  • Member Benefits
  • Contact Us
  • Accessibility Statement
  • Privacy & Cookies Notice
  • Sitemap
  • Member Login

About the National Association of Attorneys General

As the nonpartisan national forum for America's state and territory attorneys general and their staff, NAAG provides collaboration, insight, and expertise to empower and champion America's attorneys general.
Learn More

© 2025 Copyright National Association of Attorneys General

Website by Yoko Co

Internal Feedback / Report an Error

Request an Update / Report an Error

The change you are requesting will be linked to this page. The URL for the page will be included in a hidden field when the form is submitted.
Please enter your change or describe your request. Be sure to reference where the error appears on the page and what needs to be done specifically.
Upload any files that need to be linked to this page. PDF only. Submit another request if you have more than five files to upload.
Drop files here or
Accepted file types: pdf, docx, xls, Max. file size: 50 MB, Max. files: 5.

    Who is requesting this change?(Required)

    Scroll To Top
    To provide you more clarity about how we collect, store and use personal information, and your rights to control that information, we have updated our privacy policy, which also explains how we use cookies. You consent to our cookies if you continue to use our website.I Agree